

Paris, 25 October 2017

Press Release

Axyntis Group signs 3 agreements offering opportunities to develop new activities and technologies through 3 million euros of investment

In connection with CPhI Worldwide, the international pharmaceutical trade show, Axyntis Group announced that it had signed three agreements providing opportunities to develop new activities and technologies:

1. On 19 September 2017, Axyntis Group and its partner, Fuji Silysia Group, signed an agreement to build a research and development laboratory devoted to grafted silica. This is the first step towards widespread use of such products for the chromatography industry.
2. On 9 October 2017, Axyntis Group and Provepharm Life Solutions signed a new agreement to increase the Pithiviers platform's "Proveblue" production capacity. A targeted investment will enable higher production capacities for the European and American markets.
3. During CPhI, Axyntis Group and Nippon Chemicals, a listed Japanese group, entered into a strategic partnership to develop phosphorylated ligand chemistry in Axyntis's production units.

To support this growth the Axyntis group is searching to fill 20 new permanent employment positions across its sites.

CPhI also provided the opportunity to present the new range of "high potency" active ingredient manufacturing, for which Axyntis Group received financing from the French Investment Bank (BPI). Details are given in one of the videos presenting the group's principal innovative offers (www.axyntis.com/youtube).

Media Contact: Muriel Bamberger – +33 (0)1 44 06 76 96 or +33 (0)6 99 53 54 69

Created in 2007, the Axyntis Group (www.axyntis.com), an intermediate-sized company (ETI) with a turnover of more than 90M€ is, with close to 460 employees, France's fine chemicals market leader thanks to its industrial capacities*. It has two divisions: dyes, with Steiner (St Marcel), and fine chemicals, with its six factories (All'Chem in Montluçon, Centipharm in Grasse, Kyrapharm and Orgapharm in Pithiviers, and Synthexim Calaire and Dunes in Calais), three of which have R&D centres. Its activities cover various industrial subcontracting markets: life sciences, dyes and speciality fine chemicals, and are built on strategic relationships with the leading players on these markets. In addition to its Chief Executive Officer, David Simmonet who controls the share capital, Fuji Silysia Group entered into a strategic alliance with Axyntis.

*The study, « Challenges and perspectives of producers of active ingredients and drugs for third parties », March 2017, was carried out by advisors Alcimed, on behalf of PIPAME (the Interministerial Pole of Potential and Anticipated Economic Mutations (*Pôle interministériel de Prospective et d'Anticipation des Mutations économiques*)), the Ministry of the Economy and Finance, the Ministry of Foreign Affairs and International Development – Page 32